Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.040 +0.080 (+1.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 252,449
Open 4.990
Bid (Size) 4.870 (300)
Ask (Size) 5.280 (100)
Prev. Close 4.960
Today's Range 4.925 - 5.120
52wk Range 4.320 - 13.44
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+0.8%
+0.8%
1 Month
+2.0%
+2.0%
3 Month
-40.8%
-40.8%
6 Month
-41.9%
-41.9%
1 Year
-62.3%
-62.3%

More News

Read More
News headline image
Earnings Scheduled For November 12, 2025 ↗
Via Benzinga
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Alvotech announces planned CEO succession and leadership transition
From Alvotech
Via GlobeNewswire
News headline image
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Alvotech Secures Term Loan Facility of USD 100 Million
From Alvotech
Via GlobeNewswire
News headline image
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
From Alvotech
Via GlobeNewswire
News headline image
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Beyond Meat and Alvotech on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug ↗
Via Stocktwits
News headline image
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
News headline image
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Regencell, Beyond Meat, Alvotech, and Camping World and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
From Alvotech
Via GlobeNewswire

Frequently Asked Questions

Is Alvotech - Ordinary Shares publicly traded?
Yes, Alvotech - Ordinary Shares is publicly traded.
What exchange does Alvotech - Ordinary Shares trade on?
Alvotech - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alvotech - Ordinary Shares?
The ticker symbol for Alvotech - Ordinary Shares is ALVO on the Nasdaq Stock Market
What is the current price of Alvotech - Ordinary Shares?
The current price of Alvotech - Ordinary Shares is 5.040
When was Alvotech - Ordinary Shares last traded?
The last trade of Alvotech - Ordinary Shares was at 01/21/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.